Drug Manufacturers - General · NYSE
Current Price
$270.47
PE Ratio (TTM)
41.0x
Intrinsic Value
$328.06
+17.6% margin of safety
As of 2026-11-20, applying a 41.1x earnings multiple to Johnson & Johnson's (JNJ) earnings per share of $6.58 yields a fair value estimate of $328.06 per share, versus a market price of $270.47.
Fair value from earnings multiples is sensitive to the multiple you choose. Across the sensitivity grid the estimate spans $281.33 to $380.59. This is a relative estimate anchored to earnings, not a statement of fact. For a cash flow based view, see the intrinsic value estimate on the DCF page.
How the PE model works · Recalculate in PE mode · JNJ intrinsic value (DCF view)
At $270.47, JNJ trades about 17.6% below its PE-based fair value estimate, a modest discount to its earnings power, though not enough to call it cheap outright.
COMPETITIVE MOAT
↑Dominant Pharmaceutical Portfolio
JNJ possesses a vast and diversified portfolio of patented drugs, offering significant pricing power and market exclusivity. This deep pipeline ensures sustained revenue streams and competitive advantage.
↑Global Brand Recognition and Trust
The Johnson & Johnson brand is synonymous with healthcare quality and reliability worldwide. This strong reputation fosters customer loyalty and facilitates market penetration for new products.
↑Extensive R&D and Innovation Engine
JNJ's substantial investment in research and development fuels a continuous stream of innovative new drugs and medical technologies. This commitment to innovation is crucial for maintaining a competitive edge.
INVESTMENT RISKS
↓Talc Litigation and Liability Exposure
Ongoing litigation related to talc-based products presents a substantial financial and reputational risk. The potential for large settlements or judgments could significantly impact JNJ's balance sheet.
↓Drug Pricing Pressures and Political Scrutiny
Governments and payers are increasingly pushing for lower drug prices. This political and economic pressure could limit JNJ's ability to maintain current profit margins on its pharmaceuticals.
↓Execution Risk in New Product Launches
The success of JNJ's future growth hinges on the effective development and commercialization of its pipeline drugs. Any delays or failures in these launches pose a significant risk to revenue projections.
Base case
Intrinsic Value
$328.06
Margin of safety
+17.6%
Expected annual return
+3.9%
Base case assumptions: 11.8% annual earnings growth, 41.1x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Johnson & Johnson respond.
Open PE Calculator for JNJJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
PE Ratio (TTM)
41.0x
PEG Ratio
n/m
Earnings Yield
2.43%
ROE (TTM)
19.6%
Revenue/Share (TTM)
$40.59
Dividend Yield
1.95%
Debt/Equity
0.55x
The trailing twelve-month PE ratio of JNJ reflects how much investors pay per dollar of Johnson & Johnson's earnings. This metric is most useful when compared to Drug Manufacturers - General peers and the company's own historical range.
JNJ's PE of 41.0x combined with a PEG ratio of -1.12 provides a growth-adjusted perspective. JNJ has negative earnings, so its PE and PEG ratios are not meaningful here and cannot tell you whether the stock is over or undervalued. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Drug Manufacturers - General, a DCF analysis may be more appropriate.
To value Johnson & Johnson using PE: (1) Compare the current PE (41.0x) against the Drug Manufacturers - General median to assess relative pricing, (2) check the PEG ratio (-1.12) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
JNJ's PEG ratio is -1.12, calculated by dividing the PE ratio (41.0x) by the expected earnings growth rate. Because JNJ has negative earnings, its PEG ratio is not meaningful and should not be read as a sign of under or overvaluation. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how JNJ is priced versus Drug Manufacturers - General peers. DCF provides an absolute value based on projected free cash flows. For JNJ, with a strong ROE of 19.6%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value JNJ with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.